Cécile Matthews and Bhavesh Patel were quoted in Pink Sheet regarding their analysis entitled “How do rare disease patient numbers in Germany affect prices for non-oncology orphan drugs?” In Pink Sheet, Matthews and Patel discuss factors to consider when agreeing on a price including benefit ratings, patient populations, and budget impact.
Insights: Notable developments in life sciences litigation
CRA’s Life Sciences Litigation team provides periodic summaries of notable developments in litigation. In this Insights, we note an antitrust case addressing...